• Insmed reported positive 12-month open-label extension data for once-daily treprostinil palmitil inhalation powder in pulmonary arterial hypertension.
• 6-minute walk distance improved 55.7 meters in the TPIP-continued group, 54.1 meters in the placebo-crossed group.
• NT-proBNP fell about 60% in both groups; REVEAL Lite 2.0 score improved 2.0 points and 1.4 points, respectively.
• Safety through month 12 showed no new signals at doses up to 1,280 µg; 7.7% discontinued due to adverse events; four deaths were not treatment-related.
• Data support the Phase 3 PALM-PAH trial, a 24-week placebo-controlled study with 6-minute walk distance as the primary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-028602), on July 16, 2026, and is solely responsible for the information contained therein.